Study of APR-1051 in Patients With Advanced Solid Tumors

Part of paid clinical trials in Houston, Texas.

Sponsor
Aprea Therapeutics
Study ID
NCT06260514
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • APR-1051 — DRUG
    WEE1 Inhibitor

Study Details

The purpose of this study is to assess the safety and effectiveness of APR-1051 through the performance of a Phase 1, open-label, safety, PK, and preliminary efficacy study of oral APR-1051 in patients with advanced solid tumors.

Key Dates

Start date
Jun 13, 2024
Status verified
Apr 2026
Primary completion
Jun 30, 2027
Completion
Jun 30, 2028

Study Design

Enrollment
90 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: APR-1051
    Dose Escalation based on BOIN Design

Primary Outcome Measure

Treatment-related adverse events [ Time Frame: Day 1 to 28, each cycle is 28 days ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
MD Anderson Cancer Center (MDACC)HoustonTexas77030
Jessica Rhudy
[email protected]
713-745-5474
Timothy Yap, MD (PRINCIPAL_INVESTIGATOR)
NEXT Oncology -DallasIrvingTexas75039
Rebecca Popiel
[email protected]
972-893-8800
Shiraj Sen, MD (PRINCIPAL_INVESTIGATOR)
NEXT Oncology -San AntonioSan AntonioTexas78229
Jordan Georg
[email protected]
210-580-9500
David Sommerhalder, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By research site
MD Anderson Cancer Center (MDACC)· Houston, TXNEXT Oncology -Dallas· Irving, TXNEXT Oncology -San Antonio· San Antonio, TX

Related Studies